Kinase Chemistry – Just a year and a half behind the times.


Posted by kinasepro on April 25, 2007

mTOR / Pi3k inhibitor IND application reported today. XL-147 is their other one, and three pi3k applications published last Thursday. WO/2007/044698, WO/2007/044729, WO/2007/044813

Till Nature disables hotlinking: here’s who’s got what from here.


2 Responses to “XL-765”

  1. newtothefield said

    It seems like Exelixis has been extremely successful in the last three years (13 INDs with oncology applications). Do you think they are being less-selective when it comes to IND selection than other groups?

  2. kinasepro said

    Thats a pretty deep question… I know they read the blog though, so how ’bout it Ex?

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: